Argent BioPharma Limited Stock Australian S.E.

Equities

MXC

AU000000MXC6

Pharmaceuticals

Market Closed - Australian S.E. 01:45:38 2024-05-03 am EDT 5-day change 1st Jan Change
0.38 AUD -3.80% Intraday chart for Argent BioPharma Limited -6.17% -20.00%
Sales 2022 4.73M 3.13M Sales 2023 3.39M 2.24M Capitalization 16.75M 11.07M
Net income 2022 -20M -13.22M Net income 2023 -20M -13.22M EV / Sales 2022 9.75 x
Net Debt 2022 2.47M 1.63M Net Debt 2023 9.51M 6.29M EV / Sales 2023 7.75 x
P/E ratio 2022
-2.02 x
P/E ratio 2023
-0.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 9.44%
More Fundamentals * Assessed data
Dynamic Chart
1 week-8.43%
Current month-7.32%
1 month-6.17%
3 months-3.80%
6 months-20.00%
Current year-20.00%
More quotes
1 week
0.38
Extreme 0.375
0.42
1 month
0.38
Extreme 0.375
0.45
3 years
0.30
Extreme 0.3
67.00
5 years
0.30
Extreme 0.3
130.00
10 years
0.30
Extreme 0.3
130.00
More quotes
Managers TitleAgeSince
Founder 44 05-10-20
Chief Operating Officer 53 22-10-03
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Founder 44 05-10-20
Director/Board Member - 23-05-31
Director/Board Member - Nov. 30
More insiders
Date Price Change Volume
24-05-03 0.38 -3.80% 8,598
24-05-02 0.395 0.00% 2,032
24-05-01 0.395 -3.66% 4,147
24-04-30 0.41 -1.20% 32,738
24-04-29 0.415 0.00% 6,035

Delayed Quote Australian S.E., May 03, 2024 at 01:45 am EDT

More quotes
Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
More about the company

Annual profits - Rate of surprise